Onconetix (ONCO) Cash & Current Investments (2021 - 2026)
Onconetix (ONCO) posted quarterly Cash & Current Investments of $3.7 million for Q1 2026, up 135.61% year-over-year from $1.6 million in Q1 2025, and down 28.82% quarter-over-quarter from $5.2 million in Q4 2025.
Onconetix (ONCO) Cash & Current Investments (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Cash & Current Investments for 6 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments rose 135.61% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (up 135.61% YoY), while the FY2025 annual figure was $5.2 million, up 707.53% from the prior year.
- Cash & Current Investments fell to $3.7 million in Q1 2026 per ONCO's latest filing, from $5.2 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $29.1 million in Q3 2022 and bottomed at $283515.0 in Q2 2025.
- Historically, Cash & Current Investments has averaged $9.3 million across 5 years, with a median of $4.6 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Current Investments surged 1235.39% — and 2024, when it tumbled 95.54%.
- Onconetix's Cash & Current Investments stood at $25.8 million in 2022, then sank by 82.32% to $4.6 million in 2023, then tumbled by 85.8% to $646500.0 in 2024, then soared by 707.53% to $5.2 million in 2025, then retreated by 28.82% to $3.7 million in 2026.
- Business Quant data shows ONCO's Cash & Current Investments at $3.7 million in Q1 2026, $5.2 million in Q4 2025, and $836556.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 5.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.94 Mn |
| Mar 31, 2026 | 3.72 Mn |
| Dec 31, 2025 | 5.22 Mn |
| Sep 30, 2025 | 836,556.00 |
| Jun 30, 2025 | 283,515.00 |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 646,500.00 |
| Sep 30, 2024 | 341,495.00 |
| Jun 30, 2024 | 930,541.00 |
| Mar 31, 2024 | 4.46 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Sep 30, 2023 | 7.65 Mn |
| Jun 30, 2023 | 9.22 Mn |
| Mar 31, 2023 | 22.26 Mn |
| Dec 31, 2022 | 25.75 Mn |
| Sep 30, 2022 | 29.14 Mn |
| Jun 30, 2022 | 22.24 Mn |
| Mar 31, 2022 | 18.61 Mn |
| Dec 31, 2021 | 1.93 Mn |